Aprogen에이프로젠
007460 · KOSPI · ₩007460 · 에이프로젠
₩1,940▲ ₩26 (1.36%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩118B | ₩150B | ₩151B | ₩78B | ₩141B |
| Cost of sales | ₩85B | ₩115B | ₩115B | ₩72B | ₩110B |
| Gross profit | ₩33B | ₩35B | ₩36B | ₩6.2B | ₩31B |
| Operating income | −₩96B | −₩87B | −₩89B | −₩119B | −₩2.7B |
| Net income | −₩141B | −₩100B | −₩97B | −₩116B | −₩13B |
| Net income to shareholders | −₩70B | −₩58B | −₩56B | −₩99B | −₩18B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩717B | ₩610B | ₩594B | ₩600B | ₩824B |
| Current assets | ₩179B | ₩134B | ₩144B | ₩212B | ₩484B |
| Cash and equivalents | ₩45B | ₩37B | ₩36B | ₩43B | ₩62B |
| Total liabilities | ₩259B | ₩170B | ₩177B | ₩139B | ₩120B |
| Current liabilities | ₩184B | ₩113B | ₩126B | ₩90B | ₩111B |
| Borrowings | ₩186B | ₩113B | ₩124B | ₩89B | ₩78B |
| Total equity | ₩459B | ₩440B | ₩418B | ₩461B | ₩704B |
| Shareholders' equity | ₩158B | ₩159B | ₩148B | ₩215B | ₩336B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩33B | −₩45B | −₩58B | −₩113B | −₩8.6B |
| Capital spending | ₩6.6B | ₩9.5B | −₩23B | −₩20B | −₩1.4B |
| Free cash flow | −₩39B | −₩54B | −₩81B | −₩133B | −₩10B |
| Dividends paid | ₩84,588 | — | — | — | — |
Consolidated where available. Amounts in won.
Also known as: Aprogen / 에이프로젠 / 007460 / KRX:007460
Source: KRX statistical information